Geode Capital Management LLC Purchases 30,901 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Geode Capital Management LLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 1.0% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 3,060,131 shares of the biopharmaceutical company's stock after purchasing an additional 30,901 shares during the period. Geode Capital Management LLC owned 2.41% of Halozyme Therapeutics worth $175,194,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of HALO. Verdence Capital Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 1.9% during the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company's stock worth $757,000 after acquiring an additional 252 shares during the period. Fifth Third Bancorp boosted its position in Halozyme Therapeutics by 2.4% during the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company's stock worth $587,000 after purchasing an additional 261 shares during the period. GAMMA Investing LLC increased its holdings in shares of Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock valued at $50,000 after purchasing an additional 350 shares during the last quarter. Private Advisor Group LLC raised its position in shares of Halozyme Therapeutics by 1.8% in the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company's stock valued at $1,191,000 after purchasing an additional 412 shares during the period. Finally, Juncture Wealth Strategies LLC lifted its stake in shares of Halozyme Therapeutics by 3.6% during the 3rd quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company's stock worth $690,000 after buying an additional 415 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on HALO shares. Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. HC Wainwright restated a "buy" rating and issued a $68.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, November 20th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and raised their price target for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Piper Sandler increased their target price on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a "neutral" rating in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and raised their target price for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $61.11.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total transaction of $620,300.00. Following the sale, the senior vice president now directly owns 173,756 shares of the company's stock, valued at approximately $10,778,084.68. The trade was a 5.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders have sold 40,000 shares of company stock worth $2,242,100. Insiders own 2.40% of the company's stock.

Halozyme Therapeutics Price Performance

HALO traded up $0.03 during trading on Monday, hitting $48.03. 2,213,267 shares of the stock traded hands, compared to its average volume of 1,361,732. The business has a 50 day moving average price of $51.43 and a 200 day moving average price of $54.07. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53. The company has a market cap of $6.11 billion, a price-to-earnings ratio of 15.98, a PEG ratio of 0.43 and a beta of 1.23.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.